Monoclonal Antibody Deal Benchmarks in Oncology

Median Upfront

$266M

Range: $148M - $376M

Total Deal Value

$1.7B

Range: $1.1B - $2.3B

Royalty Rate

11.9% - 19.5%

Tiered up to 23.5%

Dev Milestones

$355M

Range: $237M - $475M

Model Your Deal

Market Analysis

Monoclonal Antibody therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in oncology is $266M, with total deal values reaching $1.7B. Development milestones average $355M, while regulatory milestones contribute $568M.

The oncology monoclonal antibody landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody oncology deals range from 11.9% to 19.5% at the base tier, with tiered escalation reaching 15.9%-23.5% on blockbuster sales. Commercial milestones averaging $497M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody oncology licensing deal?

Based on our analysis, Phase 2 monoclonal antibody licensing deals in oncology average $266M in upfront payments, with a range of $148M to $376M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for monoclonal antibody oncology transactions?

The median total deal value for Phase 2 monoclonal antibody assets in oncology is $1.7B, ranging from $1.1B to $2.3B. This includes development milestones ($355M), regulatory milestones ($568M), and commercial milestones ($497M).

What royalty rates are standard for monoclonal antibody deals in oncology?

Base royalty rates for monoclonal antibody oncology transactions range from 11.9% to 19.5%, with tiered escalations reaching 15.9%-23.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in monoclonal antibody oncology deals?

Monoclonal Antibody oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($355M) make up the largest share, followed by commercial milestones ($497M) and regulatory milestones ($568M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Monoclonal Antibody Deal Benchmarks in Oncology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Oncology

ADC (Antibody-Drug Conjugate) in Oncology

Monoclonal Antibody in Neurology

Monoclonal Antibody in Immunology & Autoimmune

Ready to Calculate Your Deal Terms?